<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01859793</url>
  </required_header>
  <id_info>
    <org_study_id>Merck-50600</org_study_id>
    <nct_id>NCT01859793</nct_id>
  </id_info>
  <brief_title>Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy</brief_title>
  <official_title>A Randomized, Crossover Design Study of Acute and Chronic Effects of Sitagliptin on Endothelial Function in Humans With Type 2 Diabetes on Background Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being performed to determine whether sitagliptin, a dipeptidyl peptidase-4
      inhibitor, both acutely and chronically improves blood vessel function. Patients with type 2
      diabetes who are on metformin will be enrolled in this study for up to 22 weeks in this
      double blinded cross over study where they will receive a sitagliptin pill once a day for 8
      weeks and during a separate 8 weeks receive a matching placebo pill. The treatment periods
      are divided by a 4 week period. Blood vessel function will be measured by ultrasound before
      and after a single dose of sitagliptin and placebo, as well as after 8 weeks of treatment
      with each. Blood will also be taken to measure blood markers of inflammation at each time the
      ultrasounds are performed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We plan to recruit 38 patients with T2DM for this single center, double blind randomized,
      interventional crossover trial comparing sitagliptin (100 mg/day) to matching placebo. We
      have chosen placebo over a comparator for this study as our goal is to determine whether
      sitagliptin both improves glycemic control and endothelial function, properties not shared by
      other popular classes of agents like sulfonylureas. Subjects will be randomized with a 1:1
      allocation ratio to either sitagliptin 1st or placebo 1st.

      The study have 5 total visits. Subjects who pass a phone screen will be invited to a
      screening visit for study eligibility (Visit 1) Informed consent will be reviewed; a unique
      study number will be assigned once written informed consent is obtained (no subject will be
      assigned more than 1 allocation number); relevant participant medical history will be
      recorded including currently prescribed medications; anthropometric measurements will be
      taken (height, weight, and waist circumference in metric units) and blood pressure will be
      recorded (measured in triplicate and averaged). Subjects will be allowed to take their blood
      pressure medication on the morning of their screening visit, but not the mornings of any of
      the other study visits to limit the acute influence of these medications on endothelial
      function. If the potential participant qualifies for the study, he/she will be randomized
      either to receive sitagliptin 1st (100 mg/day) or matching placebo. Prior to receiving either
      of set of pills, subjects will return to the study center within approximately 1-2 weeks of
      the screening visit to undergo initial tests of endothelial function and receive their pills.
      Prior to all study visits except screening, subjects will also be asked to refrain from any
      vigorous physical activity (no weight lifting, jogging or any activity vigorous than walking)
      24 hours to reduce the risk of fasting hypoglycemia during the study visits. Subjects will
      also be asked to fast for 6-8 hours prior to the visit to limit the acute dietary influences
      on vascular endothelial function. At Visit 2, endothelial function will determined by
      brachial artery reactivity testing prior to and following a single dose of 100 mg of
      sitagliptin or matching placebo depending on the arm to which the subject was randomized.
      Blood samples will also be taken at this visit for systemic measurements of endothelial cell
      activation/inflammation (VCAM-1 and ICAM-1) prior to and 2 hours following acute drug
      administration. These will be measured at the indicated time points using commercially
      available kits.

      Endothelial function, like the blood samples, will be measured just prior to medication
      administration and then 2 hours following medication administration by brachial artery
      reactivity testing as described in Section D.3. The 2 hour time from was chose in given the
      plasma levels of sitagliptin appear to peak 2 hours following dose administration.32 At the
      end of this visit, subjects will be given a 9 week supply of the study pills (sitagliptin or
      matching placebo) as dispensed by the Froedtert Hospital Investigational Pharmacy, and
      scheduled to return for Visit 3 approximately 8 weeks following Visit 2. Subjects will be
      asked to not take any study medication for the 24 hours prior to Visit 3. At Visit 3,
      subjects will undergo repeat testing of endothelial function. Following this study visit,
      subjects will remain off study pills until they return for Visit 4 approximately 4 weeks
      following Visit 3. Visit 4 repeats Visit 2 except subjects will receive the set of pills to
      which they had been randomized to receive second. Subjects will return to the study center
      for Visit 5 approximately 8 weeks after Visit 4. Visit 5 is identical to Visit 3. Subject
      adherence will be determined by pill counts performed by MCW Translational Research Unit
      nursing staff who will perform all pill accounting. All medication dispensation will be
      handled by the Froedtert Hospital Investigational Drug Pharmacy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brachial Artery Flow Mediated Dilation</measure>
    <time_frame>Change before and after a single dose (2 hours post) and 8 weeks after daily dosing</time_frame>
    <description>A measurement of endothelial function in humans</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Circulating Inflammatory Marker ICAM-1</measure>
    <time_frame>Change before and after acute dose (2 hours) and 8 weeks after daily dosing of medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating Inflammatory Markers VCAM-1</measure>
    <time_frame>Change before and after acute dose (2 hours) and 8 weeks after daily dosing of medication</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Diabetes</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo for Sitagliptin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100mg pill, PO administered once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sitagliptin</intervention_name>
    <description>100 mg pill, administered once/day orally</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo in appearance given once/day orally</description>
    <arm_group_label>Matching Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult age 21-70 years of age.

          2. Diagnosis of type 2 diabetes by a physician as defined by the American Diabetes
             Association standard criteria: 1) Fasting Plasma glucose at or above 126 mg/dL 2) a
             two-hour value in an oral glucose tolerance test at or above 200 mg/dL, or 3) a random
             plasma glucose concentration 200 mg/dL in the presence of symptoms, or 4) glycosylated
             hemoglobin greater than or equal to 6.5%.

          3. On stable metformin therapy for at least 6 weeks prior to enrollment.

          4. Glycosylated Hemoglobin ≥6.2% and ≤ 9.5%.

        Exclusion Criteria:

          1. History of stroke, peripheral arterial disease, or coronary artery disease (as defined
             by the presence of at least one coronary stenosis ≥ 50% on angiography or by confirmed
             history of myocardial infarction by standard criteria.)

          2. Evidence of other evident major illness including chronic renal insufficiency
             (creatinine clearance less than 60 mL/min),chronic liver disease (AST or ALT greater
             than 2.5 x normal), or cancer currently undergoing systemic therapy or had systemic
             therapy for cancer within 1 year of enrollment.

          3. Pregnancy as determined by urinary beta-HCG test

          4. Illicit drug use (heroin, cocaine etc) in the past 1 year.

          5. Alcohol abuse, defined as the equivalent of 14 beers/week for a man or 7 beers/week
             for a woman

          6. History of allergy to DPP-4 inhibitors at the time of screening/enrollment

          7. Prior history of pancreatitis

          8. Patients currently on insulin or sulfonylurea therapy.

          9. Patients currently on digoxin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael E Widlansky, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2013</study_first_submitted>
  <study_first_submitted_qc>May 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2013</study_first_posted>
  <results_first_submitted>July 18, 2016</results_first_submitted>
  <results_first_submitted_qc>August 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 21, 2016</results_first_posted>
  <last_update_submitted>August 29, 2016</last_update_submitted>
  <last_update_submitted_qc>August 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Michael E. Widlansky</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>dipeptidyl peptidase-4 inhibitor</keyword>
  <keyword>endothelium, vascular</keyword>
  <keyword>diabetes type 2</keyword>
  <keyword>nitric oxide</keyword>
  <keyword>inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data set may be shared in a de-identified manner by request from qualified investigators with appropriate qualifications</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo 1st Then Sitagliptin</title>
          <description>Matching Placebo for Sitagliptin
Placebo: Matching placebo in appearance given once/day orally for 8 weeks followed by 8 weeks of 100 mg sitaglipin/day separated by a 4 week washout period</description>
        </group>
        <group group_id="P2">
          <title>Sitagliptin First Then Placebo</title>
          <description>sitagliptin: 100 mg pill, administered once/day orally for 8 weeks followed by matching placebo for 8 weeks following a 4 week washout period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (8 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>2nd Intervention Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Matching Placebo 1st</title>
          <description>Matching Placebo for Sitagliptin
Placebo: Matching placebo in appearance given once/day orally</description>
        </group>
        <group group_id="B2">
          <title>Sitagliptin 1st</title>
          <description>100mg pill, PO administered once daily.
sitagliptin: 100 mg pill, administered once/day orally</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" spread="10"/>
                    <measurement group_id="B2" value="63" spread="9"/>
                    <measurement group_id="B3" value="63" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.1" spread="6.6"/>
                    <measurement group_id="B2" value="32.6" spread="6.3"/>
                    <measurement group_id="B3" value="32.4" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HgA1C</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.8" spread="0.2"/>
                    <measurement group_id="B2" value="6.9" spread="0.8"/>
                    <measurement group_id="B3" value="6.8" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heart Rate</title>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" spread="10"/>
                    <measurement group_id="B2" value="76" spread="8"/>
                    <measurement group_id="B3" value="74" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131" spread="13"/>
                    <measurement group_id="B2" value="136" spread="15"/>
                    <measurement group_id="B3" value="134" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73" spread="11"/>
                    <measurement group_id="B2" value="78" spread="20"/>
                    <measurement group_id="B3" value="75" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Cholesterol</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165" spread="31"/>
                    <measurement group_id="B2" value="169" spread="29"/>
                    <measurement group_id="B3" value="167" spread="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High Density Lipoprotein</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" spread="12"/>
                    <measurement group_id="B2" value="56" spread="20"/>
                    <measurement group_id="B3" value="55" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low Density Lipoprotein</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85" spread="29"/>
                    <measurement group_id="B2" value="84" spread="26"/>
                    <measurement group_id="B3" value="84" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126" spread="53"/>
                    <measurement group_id="B2" value="138" spread="40"/>
                    <measurement group_id="B3" value="132" spread="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insulin</title>
          <units>microU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.1" spread="5.6"/>
                    <measurement group_id="B2" value="16.0" spread="8.9"/>
                    <measurement group_id="B3" value="15.6" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glucose</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117" spread="26"/>
                    <measurement group_id="B2" value="134" spread="31"/>
                    <measurement group_id="B3" value="126" spread="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Homeostatic Assessment of Insulin Resistance</title>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.4" spread="1.9"/>
                    <measurement group_id="B2" value="5.3" spread="2.9"/>
                    <measurement group_id="B3" value="4.9" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alanine Aminotransferase (ALT)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" spread="30"/>
                    <measurement group_id="B2" value="28" spread="23"/>
                    <measurement group_id="B3" value="29" spread="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Aspartate Aminotransferase (AST)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" spread="17"/>
                    <measurement group_id="B2" value="25" spread="13"/>
                    <measurement group_id="B3" value="25" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Bilirubin</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.4" spread="0.2"/>
                    <measurement group_id="B2" value="0.5" spread="0.3"/>
                    <measurement group_id="B3" value="0.5" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alkaline Phosphatase</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73" spread="10"/>
                    <measurement group_id="B2" value="78" spread="20"/>
                    <measurement group_id="B3" value="78" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Hypertension</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>With Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of High Cholesterol</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>With Dyslipidemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without Dyslipidemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Past or Current</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ACE Inhibitor</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Beta-Blocker</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HMG CoA-Reductase</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Brachial Artery Flow Mediated Dilation</title>
        <description>A measurement of endothelial function in humans</description>
        <time_frame>Change before and after a single dose (2 hours post) and 8 weeks after daily dosing</time_frame>
        <population>All 30 subjects who completed both arms of the cross-over study</population>
        <group_list>
          <group group_id="O1">
            <title>Matching Placebo</title>
            <description>Matching Placebo for Sitagliptin
Placebo: Matching placebo in appearance given once/day orally</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin</title>
            <description>100mg pill, PO administered once daily.
sitagliptin: 100 mg pill, administered once/day orally</description>
          </group>
        </group_list>
        <measure>
          <title>Brachial Artery Flow Mediated Dilation</title>
          <description>A measurement of endothelial function in humans</description>
          <population>All 30 subjects who completed both arms of the cross-over study</population>
          <units>%FMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Prior To Intervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="1.8"/>
                    <measurement group_id="O2" value="5.6" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post acute dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="2.1"/>
                    <measurement group_id="O2" value="6.3" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Following 8 weeks of therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="2.9"/>
                    <measurement group_id="O2" value="5.8" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Primary and secondary outcome variables were compared across measurement periods by repeated measures ANOVA and post hoc analyses using Tukey’s test were applied if significant differences were detected. A priori sample size calculation demonstrated our study design has 80% power to detect a 1.5% absolute increase in FMD% with 30 subjects completing the entire study protocol at α=0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Circulating Inflammatory Marker ICAM-1</title>
        <time_frame>Change before and after acute dose (2 hours) and 8 weeks after daily dosing of medication</time_frame>
        <population>29 of the 30 subjects who completed both arms of the study. One subject was missing the measurements post 8 weeks of each intervention arm and was excluded</population>
        <group_list>
          <group group_id="O1">
            <title>Matching Placebo</title>
            <description>Matching Placebo for Sitagliptin
Placebo: Matching placebo in appearance given once/day orally</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin</title>
            <description>100mg pill, PO administered once daily.
sitagliptin: 100 mg pill, administered once/day orally</description>
          </group>
        </group_list>
        <measure>
          <title>Circulating Inflammatory Marker ICAM-1</title>
          <population>29 of the 30 subjects who completed both arms of the study. One subject was missing the measurements post 8 weeks of each intervention arm and was excluded</population>
          <units>mg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Intervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226" spread="72"/>
                    <measurement group_id="O2" value="223" spread="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post acute dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216" spread="73"/>
                    <measurement group_id="O2" value="211" spread="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post 8 weeks of therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228" spread="73"/>
                    <measurement group_id="O2" value="232" spread="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Outcome variables were compared across measurement periods by repeated measures ANOVA and post hoc analyses using Tukey’s test were applied if significant differences were detected</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Circulating Inflammatory Markers VCAM-1</title>
        <time_frame>Change before and after acute dose (2 hours) and 8 weeks after daily dosing of medication</time_frame>
        <population>29 of the 30 subject who completed the study. Once subject had missing data for the post-8 weeks of each intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Matching Placebo</title>
            <description>Matching Placebo for Sitagliptin
Placebo: Matching placebo in appearance given once/day orally</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin</title>
            <description>100mg pill, PO administered once daily.
sitagliptin: 100 mg pill, administered once/day orally</description>
          </group>
        </group_list>
        <measure>
          <title>Circulating Inflammatory Markers VCAM-1</title>
          <population>29 of the 30 subject who completed the study. Once subject had missing data for the post-8 weeks of each intervention</population>
          <units>mg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Intervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="584" spread="187"/>
                    <measurement group_id="O2" value="608" spread="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post acute dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="575" spread="141"/>
                    <measurement group_id="O2" value="574" spread="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post 8 weeks of therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="620" spread="196"/>
                    <measurement group_id="O2" value="620" spread="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Outcome variables were compared across measurement periods by repeated measures ANOVA and post hoc analyses using Tukey’s test were applied if significant differences were detected</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Matching Placebo</title>
          <description>Matching Placebo for Sitagliptin
Placebo: Matching placebo in appearance given once/day orally</description>
        </group>
        <group group_id="E2">
          <title>Sitagliptin</title>
          <description>100mg pill, PO administered once daily.
sitagliptin: 100 mg pill, administered once/day orally</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <description>1 subject developed a minor rash along the subjects belt line during the study and was withdrawn from the study. The subject was on placebo at the time as discovered following unblinding</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No limitations noted.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Michael E. Widlansky</name_or_title>
      <organization>Medical College of Wisconsin</organization>
      <phone>414-955-6806</phone>
      <email>mwidlans@mcw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

